Jun. 21, 2017

Novopyxis – The first start-up identified by LEO Science & Tech Hub

LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.

The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.

Read the press release

News from the hub

Oct. 2017 11 LEO Science & Tech Hub Announces a Collaboration with Elektrofi for Formulation Technology to Improve Dermatological Drug Delivery

LEO Science & Tech Hub, today announced a collaboration agreement with Elektrofi, a Cambridge-based biotechnology company focused on drug delivery innovations, to explore advanced formulation technology for dermatological drug delivery. “We are excited to announce this collaboration with Elektrofi to explore its innovative Elektroject™ process technology to increase our options in subcutaneous delivery of antibodies” […]

Read more
Aug. 2017 23 LEO Science & Tech Hub Announces Collaborations with MGH Wellman Center for Photomedicine to Explore Imaging Technology and Develop Microbiopsy Device

The Hub today announced two collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital. The Hub will provide research funding to support development of novel imaging technology with the laboratory led by Conor L. Evans, Ph.D., Assistant Professor, Harvard Medical School, and a disposable microbiopsy device with Walfre Franco, Ph.D., Instructor, and […]

Read more